NC BioStart

1
NC BioStart

• Translation through Commercialization

2
Who we are

• Dr. Richard Boucher Executive Director
• Don Rose, Ph.D. Director
• Ilona Ori Program Assistant
• Justin Brown, Ph.D. Visiting Scholar,
  Entrepreneurship
• Entrepreneurs-in-Residence
• Tom Mercolino, Ph.D
• Joel Shaffer, Ph.D.
• Perry Genova, Ph.D.

3
Rationale

• Value of University Startups
• Translation through Commercialization
• Faculty Recruitment and Retention
• Increase Value of University Assets
• Economic Development
• Build on current efforts at UNC to foster
  startups
• Launching the Venture (KFBS)
• Carolina Express License (OTD)

4
Program Overview

• Mission
• Facilitate and accelerate University startups
• Scope
• Life science (drugs, devices, diagnostics, tools)
• Breadth
• Today UNC-CH campus
• Future All state-supported campuses
• Location and Funding
• NC Translational and Clinical Sciences Institute
• Home of NIH CTSA Grant (Etta Pisano, PI)

5
NC BioStart
6
(No Transcript)
7
Tom Mercolino

• PhD (UNC88) Microbiology Immunology
• BS Chemistry
• Registered Patent Agent
• gt25 Years in Pharma Diagnostics RD Management
• Becton Dickinson
• Johnson Johnson
• Entrepreneur
• Founder CEO of CertiRx

7
8
Tom Mercolino

• Representative Client Companies
• Rheomics - early
• College of Arts Sciences (Prof. Physics
  Department)
• Re-focused technology platform to high-value
  applications
• Hepa Ca Dx - nascent
• UNC Gillings School of Global Public Health (PhD
  Student)
• organizing clinical proof of principle
• X-In8 - established
• School of Medicine (Prof. surgery)
• Id and resolution of potential patent issue in
  partnership with OTD

8
9
Joel Shaffer

• Entrepreneur in Residence
• for Therapeutics

9
10
Resume

• 5 yrs at American Critical Care (DuPont)
• 17 yrs at Glaxo (GW, GSK)
• Business Development for Metabolic Diseases
• Head of Pharmacology
• High-throughput screening
• Preclinical Project leader
• RD in Cardiovascular, Oncology, Urology,
  Metabolic Diseases

10
11
Entrepreneur-in-Residence at UNC May 2009

• Advising 7 UNC clients
• Enci Therapeutics
• Hibernaid
• Novolipid
• Synereca
• (Scott Singleton, Ph.D. Med. Chem. natural prod.)
• G-zero
• (Ned Sharpless, M.D. Medicine, genetics)
• Matt Redinbo, Ph.D. Chemistry, structural
  chemistry
• Mark Zylka, Ph.D. Cell Molecular Physiology

11
12
Enci Therapeutics

• Cam Patterson, M.D. and Nancy DeMore, M.D.
• Discovery of new angiogenesis factor (SFRP2)
• Developed a mouse mAb
• The antibody blunts tumor growth
• How does this target compare to VEGF?
• How do we make a human mAb for clinical testing?

12
13
Hibernaid

• Larry Katz, M.D.
• Has studied hypothermia mechanisms for years
• Ice baths improve outcome for pts with cardiac
  arrest
• Discovered that certain agents used in
  combination (unexpectedly) lower the bodys
  temperature set point
• Determined a fixed combination of agents will
• Lower temp by 4-5 oC
• Increase survival after acute cardiac arrest in
  rats and pigs
• Improve CNS performance post injury
• Will this benefit patients suffering from
  reperfusion injury?

13
14
Novolipid

• Mike Hackett and Deepak Gopalakrishna
• Graduate students, Pharmacy and Molecular Biology
• Discovered that they could covalently attach
  cytotoxic chemotherapeutic drugs to small lipids
  which have high affinity to albumin
• Longer half-life
• Less systemic toxicity of drug
• No need for toxic solvents
• Better tumor penetration
• Will this show superior effects in animals and
  humans?

14
15
Perry Genova

• MS, PhD Biomedical Engineering
• BS EE, BME
• Serial entrepreneur (IEP, Quill, Oncoscope)
• Global VP GSK (MDI business France)
• VP Kos Pharmaceuticals
• Inhaled product development including insulin
• Worked for Adrian Adams (CEO Inspire)

15
16
Katharos Improving care for dialysis patients

• Melanie Joy (UNC) and Marian McCord (NCSU)
• Addresses large unmet need (160,000 patients)
• Remove excess phosphate from blood during
  dialysis
• High phosphate associated with morbidity and
  mortality
• Technology combines phosphate adsorption
  chemistry with filtration science
• Improved compliance, no side effects
• TraCS grant supported feasibility work
• TAM 25M devices, 2.5B market

17
Contact Information

• Don Rose
• Director, NC BioStart
• donrose_at_email.unc.edu
• www.ncbiostart.com
• Ilona Ori
• Program Assistant
• ilona_ori_at_med.unc.edu
• 919-843-3304
• Upcoming Events
• Commercialization Webinar
• Incorporation and Founders Stock
• Ken Eheman and Anthony Williams, WRYP
• March 15th, 12 1 pm
• Emerging Company Showcase
• April 12th, 6 pm, Kenan-Flagler Business School